S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

OBJECTIVE: The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l-leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastatic...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:ESMO Open
Main Authors: Baba, Hideo, Yamada, Yasuhide, Takahari, Daisuke, Matsumoto, Hiroshi, Yoshida, Kazuhiro, Nakamura, Masato, Yoshida, Motoki, Iwamoto, Shigeyoshi, Shimada, Ken, Komatsu, Yoshito, Sasaki, Yasutsuna, Satoh, Taroh, Takahashi, Keiichi, Mishima, Hideyuki, Muro, Kei, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Sugihara, Kenichi
פורמט: Artigo
שפה:Inglês
יצא לאור: ESMO Open 2017
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519807/
https://ncbi.nlm.nih.gov/pubmed/28761727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000135
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים